Fuchs Dystrophy Clinical Trial
Official title:
Association Between Fuchs' Endothelial Corneal Dystrophy Severity and Estrogen Exposure
Verified date | August 2023 |
Source | State University of New York at Buffalo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is being done to discover if there is a link between estrogen exposure and the severity of Fuchs Endothelial Corneal Disease. We are trying to understand if the decrease in estrogen levels in post-menopausal women may be a reason why FECD is seen more often in women than men.
Status | Active, not recruiting |
Enrollment | 43 |
Est. completion date | June 30, 2024 |
Est. primary completion date | April 27, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years and older |
Eligibility | Inclusion Criteria: 1. Individuals with FECD grade 1-2/7 (mild) or 5-6/7 (severe) in one or both eyes 2. Age = 55 3. Phakic and pseudophakic individuals will be included. Pseudophakic patients must have evidence of routine cataract surgery (posterior chamber intraocular lens in-the-bag without clinical evidence of damage to any intraocular structures). Exclusion Criteria: 1. Females are excluded if not post-menopause. 2. Pseudophakic patients with a history of complex cataract surgery or other intraocular surgery (e.g. have an anterior chamber lens, sulcus lens, or poorly positioned posterior chamber lens, aphakia, iris damage, glaucoma surgery) will be excluded due to risk of iatrogenic damage to the corneal endothelium. |
Country | Name | City | State |
---|---|---|---|
United States | The Ira G. Ross Eye Institute | Buffalo | New York |
Lead Sponsor | Collaborator |
---|---|
State University of New York at Buffalo |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Association Between Fuchs endothelial Corneal Dystophy Severity and Estrogen Exposure | Difference in measures of estriadiol exposure between individuals with mild vs. severe FECD | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04527523 -
Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only
|
||
Completed |
NCT03763721 -
The ADVISE Study: Advanced Visualization In Corneal Surgery Evaluation
|
N/A | |
Recruiting |
NCT04191629 -
Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema
|
Phase 1 | |
Recruiting |
NCT05853978 -
The Evaluation of Balanced Salt Solution During Cataract Surgery
|
Phase 4 | |
Recruiting |
NCT03575130 -
Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy
|
Phase 2 | |
Recruiting |
NCT04258787 -
OCT in Fuchs' Dystrophy
|
||
Active, not recruiting |
NCT04894110 -
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
|
Phase 1 | |
Completed |
NCT00346138 -
A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema
|
N/A | |
Recruiting |
NCT05275972 -
Descemet Endothelial Thickness Comparison Trial II
|
Phase 3 | |
Completed |
NCT04676737 -
TTHX1114(NM141) in Combination With DWEK/DSO
|
Phase 2 | |
Recruiting |
NCT03619434 -
Femtolaser Assisted Keratoplasty Versus Conventional Keratoplasty
|
N/A | |
Recruiting |
NCT05636579 -
Study to Assess Safety and Tolerability of Multiple Doses of EO2002
|
Phase 1 |